Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
- Preliminary data generated from our pilot protocol 02-C-0064 suggests that the urinary
VEGF and MMP level at the one month follow-up time point compared to the last
on-treatment time point collection may be predictive of tumor recurrence at one year
- Note that this preliminary study included patients with all histologies.
- In an on ongoing effort to validate our results with a larger more homogeneous patient
cohort we propose to prospectively study patients undergoing radiotherapy for GBM.
-We will determine the whether VEGF and MMP level measurements aide in predicting tumor
recurrence at 1 year.
-Patients seen in the radiation oncology clinic will be asked to provide samples of blood
and urine before, during and after their radiation treatment.
- This protocol-provides a means of acquiring blood and urine samples from patients
receiving radiation therapy for Glioblastoma multiforme (GBM).
- Patients will be stratified according to their Radiation Therapy Oncology Group (RTOG)
recursive partitioning prognostic subgroups, which includes patient age, KPS, extent of
resection and neurological function.
Kevin A Camphausen, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|